![Michael Wacker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Wacker
Fondateur chez LimmaTech Biologics AG
Postes actifs de Michael Wacker
Sociétés | Poste | Début | Fin |
---|---|---|---|
Inositec AG
![]() Inositec AG Pharmaceuticals: MajorHealth Technology Inositec AG develops small molecules as alternatives to antibiotics. It also develops a non-antibiotic small molecule that neutralizes the toxins secreted by clostridium toxins. The company was founded by Mattias Ivarsson, Bastien Castagner and Jean-Christophe Leroux in December 2015 and is headquartered in Zurich, Switzerland. | Président | - | - |
Tubulis GmbH
![]() Tubulis GmbH Pharmaceuticals: MajorHealth Technology Tubulis GmbH engages in biotechnology company. The firm develops matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. The company was founded by Dominik Schumacher and Jonas Helma-Smets and is headquartered in Munich, Germany. | Directeur/Membre du Conseil | - | - |
LimmaTech Biologics AG
![]() LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Directeur/Membre du Conseil | 01/01/2015 | - |
Fondateur | 01/01/2015 | - | |
Scenic Biotech BV
![]() Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Michael Wacker
Anciens postes connus de Michael Wacker
Sociétés | Poste | Début | Fin |
---|---|---|---|
Swiss Federal Institute of Technology | Corporate Officer/Principal | - | - |
Polyneuron Pharmaceuticals AG
![]() Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | Directeur/Membre du Conseil | 01/01/2018 | - |
Corporate Officer/Principal | 01/01/2018 | - | |
GlycoVaxyn AG
![]() GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Directeur/Membre du Conseil | 05/11/2004 | - |
Directeur Technique/Scientifique/R&D | 05/11/2004 | - | |
Fondateur | 05/05/2010 | - |
Formation de Michael Wacker
Swiss Federal Institute of Technology | Doctorate Degree |
Statistiques
Internationale
Suisse | 6 |
Allemagne | 2 |
Pays-Bas | 2 |
Opérationnelle
Director/Board Member | 5 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Sectorielle
Health Technology | 5 |
Commercial Services | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 6 |
---|---|
GlycoVaxyn AG
![]() GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Health Technology |
Polyneuron Pharmaceuticals AG
![]() Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Inositec AG
![]() Inositec AG Pharmaceuticals: MajorHealth Technology Inositec AG develops small molecules as alternatives to antibiotics. It also develops a non-antibiotic small molecule that neutralizes the toxins secreted by clostridium toxins. The company was founded by Mattias Ivarsson, Bastien Castagner and Jean-Christophe Leroux in December 2015 and is headquartered in Zurich, Switzerland. | Health Technology |
Tubulis GmbH
![]() Tubulis GmbH Pharmaceuticals: MajorHealth Technology Tubulis GmbH engages in biotechnology company. The firm develops matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. The company was founded by Dominik Schumacher and Jonas Helma-Smets and is headquartered in Munich, Germany. | Health Technology |
LimmaTech Biologics AG
![]() LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Commercial Services |
Scenic Biotech BV
![]() Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Commercial Services |
- Bourse
- Insiders
- Michael Wacker
- Expérience